{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:02:35Z","timestamp":1781222555343,"version":"3.54.1"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30-EY026877"],"award-info":[{"award-number":["P30-EY026877"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30-EY026877"],"award-info":[{"award-number":["P30-EY026877"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Fund of China","doi-asserted-by":"crossref","award":["82388101"],"award-info":[{"award-number":["82388101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Natural Science Foundation","award":["IS23096"],"award-info":[{"award-number":["IS23096"]}]},{"name":"National Key R&D Program","award":["2022YFC2502800"],"award-info":[{"award-number":["2022YFC2502800"]}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council, Singapore","doi-asserted-by":"crossref","award":["NMCR\/HSRG\/0087\/2018, MOH-000655-00 and MOH-001014-00"],"award-info":[{"award-number":["NMCR\/HSRG\/0087\/2018, MOH-000655-00 and MOH-001014-00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","award":["A20H4g2141 and H20C6a0032"],"award-info":[{"award-number":["A20H4g2141 and H20C6a0032"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016017","name":"Duke-NUS Medical School","doi-asserted-by":"publisher","award":["Duke-NUS\/RSF\/2021\/0018 and 05\/FY2020\/EX\/15-A58, 05\/FY2022\/EX\/66-A128"],"award-info":[{"award-number":["Duke-NUS\/RSF\/2021\/0018 and 05\/FY2020\/EX\/15-A58, 05\/FY2022\/EX\/66-A128"]}],"id":[{"id":"10.13039\/100016017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000615","name":"Fight for Sight UK","doi-asserted-by":"publisher","award":["MR\/T001674\/1"],"award-info":[{"award-number":["MR\/T001674\/1"]}],"id":[{"id":"10.13039\/501100000615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024501","name":"Birmingham Health Partners","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024501","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MRC Proximity to Discovery and Impact (P2D) Fund","award":["MR\/X502996\/1"],"award-info":[{"award-number":["MR\/X502996\/1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-025-01954-y","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:10:01Z","timestamp":1758795001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ophthalmic drug discovery and development using artificial intelligence and digital health technologies"],"prefix":"10.1038","volume":"8","author":[{"given":"Haoran","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy Le Yi","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrystie Wan Ning","family":"Quek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinit B.","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodhbir S.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S. W.","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren S. J.","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"1954_CR1","doi-asserted-by":"publisher","first-page":"e2415445","DOI":"10.1001\/jamanetworkopen.2024.15445","volume":"7","author":"A Sertkaya","year":"2024","unstructured":"Sertkaya, A., Beleche, T., Jessup, A. & Sommers, B. D. Costs of drug development and research and development intensity in the US, 2000-2018. JAMA Netw. Open 7, e2415445 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1954_CR2","unstructured":"Spherical Insights LLP. Global Ophthalmic Drugs Market Size, Share, and COVID-19 Impact Analysis, by Disease, Drug Class, Dosage, Administration, Product, and Region, Forecast to 2030. (published February 2023; accessed 20 August 2025)."},{"key":"1954_CR3","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","volume":"114","author":"IU Scott","year":"2007","unstructured":"Scott, I. U. et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114, 1860\u20131867 (2007).","journal-title":"Ophthalmology"},{"key":"1954_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld, P. J., Moshfeghi, A. A. & Puliafito, C. A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg. Lasers Imaging 36, 331\u2013335 (2005).","journal-title":"Ophthalmic Surg. Lasers Imaging"},{"key":"1954_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung, N., Mitchell, P. & Wong, T. Y. Diabetic retinopathy. Lancet 376, 124\u2013136 (2010).","journal-title":"Lancet"},{"key":"1954_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.12","volume":"2","author":"TY Wong","year":"2016","unstructured":"Wong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S. & Sim\u00f3, R. Diabetic retinopathy. Nat. Rev. Dis. Prim. 2, 16012 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1954_CR7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell, P., Liew, G., Gopinath, B. & Wong, T. Y. Age-related macular degeneration. Lancet 392, 1147\u20131159 (2018).","journal-title":"Lancet"},{"key":"1954_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","volume":"153","author":"SB Bloch","year":"2012","unstructured":"Bloch, S. B., Larsen, M. & Munch, I. C. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am. J. Ophthalmol. 153, 209\u2013213.e202 (2012).","journal-title":"Am. J. Ophthalmol."},{"key":"1954_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ajo.2022.03.010","volume":"240","author":"A Israeli","year":"2022","unstructured":"Israeli, A., Peer, H., Gleitman, I., Falick, Y. & Mezer, E. Time trends of etiologies of blindness in Israel 2009-2020: have methods to decrease leading causes of blindness been exhausted?. Am. J. Ophthalmol. 240, 149\u2013158 (2022).","journal-title":"Am. J. Ophthalmol."},{"key":"1954_CR10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell, S. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390, 849\u2013860 (2017).","journal-title":"Lancet"},{"key":"1954_CR11","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/s41433-024-03049-6","volume":"38","author":"RRA Bourne","year":"2024","unstructured":"Bourne, R. R. A. et al. The UK clinical eye research strategy: refreshing research priorities for clinical eye research in the UK. Eye 38, 1947\u20131957 (2024).","journal-title":"Eye"},{"key":"1954_CR12","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/S2589-7500(20)30088-1","volume":"2","author":"T Burki","year":"2020","unstructured":"Burki, T. A new paradigm for drug development. Lancet Digit. Health 2, e226\u2013e227 (2020).","journal-title":"Lancet Digit. Health"},{"key":"1954_CR13","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.cell.2020.01.021","volume":"180","author":"JM Stokes","year":"2020","unstructured":"Stokes, J. M. et al. A deep learning approach to antibiotic discovery. Cell 180, 688\u2013702.e613 (2020).","journal-title":"Cell"},{"key":"1954_CR14","doi-asserted-by":"publisher","first-page":"100947","DOI":"10.1016\/j.lanmic.2024.07.010","volume":"6","author":"CS Ho","year":"2025","unstructured":"Ho, C. S. et al. Antimicrobial resistance: a concise update. Lancet Microbe 6, 100947. https:\/\/doi.org\/10.1016\/j.lanmic.2024.07.010 (2025).","journal-title":"Lancet Microbe"},{"key":"1954_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/d41586-023-02896-9","volume":"621","author":"M Mock","year":"2023","unstructured":"Mock, M., Edavettal, S., Langmead, C. & Russell, A. AI can help to speed up drug discovery\u2014but only if we give it the right data. Nature 621, 467\u2013470 (2023).","journal-title":"Nature"},{"key":"1954_CR16","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1016\/j.drudis.2021.06.009","volume":"26","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. AI-based language models powering drug discovery and development. Drug Discov. Today 26, 2593\u20132607 (2021).","journal-title":"Drug Discov. Today"},{"key":"1954_CR17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.5662\/wjm.v13.i4.170","volume":"13","author":"M Jeyaraman","year":"2023","unstructured":"Jeyaraman, M. et al. ChatGPT in action: harnessing artificial intelligence potential and addressing ethical challenges in medicine, education, and scientific research. World J. Methodol. 13, 170\u2013178 (2023).","journal-title":"World J. Methodol."},{"key":"1954_CR18","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1038\/s41591-023-02448-8","volume":"29","author":"AJ Thirunavukarasu","year":"2023","unstructured":"Thirunavukarasu, A. J. et al. Large language models in medicine. Nat. Med. 29, 1930\u20131940 (2023).","journal-title":"Nat. Med."},{"key":"1954_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","volume":"31","author":"K Zhang","year":"2025","unstructured":"Zhang, K. et al. Artificial intelligence in drug development. Nat. Med. 31, 45\u201359 (2025).","journal-title":"Nat. Med."},{"key":"1954_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.tips.2019.05.005","volume":"40","author":"S Harrer","year":"2019","unstructured":"Harrer, S., Shah, P., Antony, B. & Hu, J. Artificial intelligence for clinical trial design. Trends Pharmacol. Sci. 40, 577\u2013591 (2019).","journal-title":"Trends Pharmacol. Sci."},{"key":"1954_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44385-024-00003-9","volume":"2","author":"Q Liao","year":"2025","unstructured":"Liao, Q. et al. Application of artificial intelligence in drug-target interactions prediction: a review. npj Biomed. Innov. 2, 1 (2025).","journal-title":"npj Biomed. Innov."},{"key":"1954_CR22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","volume":"616","author":"AV Sadybekov","year":"2023","unstructured":"Sadybekov, A. V. & Katritch, V. Computational approaches streamlining drug discovery. Nature 616, 673\u2013685 (2023).","journal-title":"Nature"},{"key":"1954_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2022.101157","volume":"88","author":"J Weinberg","year":"2022","unstructured":"Weinberg, J., Gaur, M., Swaroop, A. & Taylor, A. Proteostasis in aging-associated ocular disease. Mol. Asp. Med. 88, 101157 (2022).","journal-title":"Mol. Asp. Med."},{"key":"1954_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jare.2020.05.012","volume":"24","author":"A Venkatraman","year":"2020","unstructured":"Venkatraman, A., Duong-Thi, M. D., Pervushin, K., Ohlson, S. & Mehta, J. S. Pharmaceutical modulation of the proteolytic profile of Transforming Growth Factor Beta induced protein (TGFBIp) offers a new avenue for treatment of TGFBI-corneal dystrophy. J. Adv. Res. 24, 529\u2013543 (2020).","journal-title":"J. Adv. Res."},{"key":"1954_CR25","doi-asserted-by":"publisher","unstructured":"Burley, S. K. et al. Protein Data Bank: a comprehensive review of 3D structure holdings and worldwide utilization by researchers, educators, and students. Biomolecules 12, https:\/\/doi.org\/10.3390\/biom12101425 (2022).","DOI":"10.3390\/biom12101425"},{"key":"1954_CR26","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41586-019-1923-7","volume":"577","author":"AW Senior","year":"2020","unstructured":"Senior, A. W. et al. Improved protein structure prediction using potentials from deep learning. Nature 577, 706\u2013710 (2020).","journal-title":"Nature"},{"key":"1954_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"1954_CR28","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"1954_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-023-02429-z","volume":"10","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. Structure prediction of novel isoforms from uveal melanoma by AlphaFold. Sci. Data 10, 513 (2023).","journal-title":"Sci. Data"},{"key":"1954_CR30","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1021\/acs.jcim.3c01619","volume":"64","author":"P Kamya","year":"2024","unstructured":"Kamya, P. et al. PandaOmics: an AI-driven platform for therapeutic target and biomarker discovery. J. Chem. Inf. Model. 64, 3961\u20133969 (2024).","journal-title":"J. Chem. Inf. Model."},{"key":"1954_CR31","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41551-024-01201-x","volume":"8","author":"F Wan","year":"2024","unstructured":"Wan, F., Torres, M. D. T., Peng, J. & de la Fuente-Nunez, C. Deep-learning-enabled antibiotic discovery through molecular de-extinction. Nat. Biomed. Eng. 8, 854\u2013871 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1954_CR32","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.chom.2023.07.001","volume":"31","author":"J Maasch","year":"2023","unstructured":"Maasch, J., Torres, M. D. T., Melo, M. C. R. & de la Fuente-Nunez, C. Molecular de-extinction of ancient antimicrobial peptides enabled by machine learning. Cell Host Microbe 31, 1260\u20131274.e1266 (2023).","journal-title":"Cell Host Microbe"},{"key":"1954_CR33","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1016\/j.cell.2024.07.027","volume":"187","author":"MDT Torres","year":"2024","unstructured":"Torres, M. D. T. et al. Mining human microbiomes reveals an untapped source of peptide antibiotics. Cell 187, 5453\u20135467.e5415 (2024).","journal-title":"Cell"},{"key":"1954_CR34","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1016\/j.cell.2024.05.013","volume":"187","author":"CD Santos-J\u00fanior","year":"2024","unstructured":"Santos-J\u00fanior, C. D. et al. Discovery of antimicrobial peptides in the global microbiome with machine learning. Cell 187, 3761\u20133778.e3716 (2024).","journal-title":"Cell"},{"key":"1954_CR35","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1039\/D3DD00004D","volume":"2","author":"J Redshaw","year":"2023","unstructured":"Redshaw, J., Ting, D. S. J., Brown, A., Hirst, J. D. & G\u00e4rtner, T. Krein support vector machine classification of antimicrobial peptides. Digital Discov. 2, 502\u2013511 (2023).","journal-title":"Digital Discov."},{"key":"1954_CR36","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1021\/acscentsci.0c00229","volume":"6","author":"F Gentile","year":"2020","unstructured":"Gentile, F. et al. Deep docking: a deep learning platform for augmentation of structure based drug discovery. ACS Cent. Sci. 6, 939\u2013949 (2020).","journal-title":"ACS Cent. Sci."},{"key":"1954_CR37","doi-asserted-by":"publisher","unstructured":"Luttens, A. et al. Rapid traversal of vast chemical space using machine learning-guided docking screens. Nat. Comput. Sci. https:\/\/doi.org\/10.1038\/s43588-025-00777-x (2025).","DOI":"10.1038\/s43588-025-00777-x"},{"key":"1954_CR38","doi-asserted-by":"publisher","unstructured":"Ren, F. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02143-0 (2024).","DOI":"10.1038\/s41587-024-02143-0"},{"key":"1954_CR39","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","volume":"99","author":"SA Hollingsworth","year":"2018","unstructured":"Hollingsworth, S. A. & Dror, R. O. Molecular dynamics simulation for all. Neuron 99, 1129\u20131143 (2018).","journal-title":"Neuron"},{"key":"1954_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s10462-024-10731-4","volume":"57","author":"E Pra\u0161nikar","year":"2024","unstructured":"Pra\u0161nikar, E., Ljubi\u010d, M., Perdih, A. & Bori\u0161ek, J. Machine learning heralding a new development phase in molecular dynamics simulations. Artif. Intell. Rev. 57, 102 (2024).","journal-title":"Artif. Intell. Rev."},{"key":"1954_CR41","doi-asserted-by":"publisher","unstructured":"Ting, D. S. J. et al. Evaluation of host defense peptide (CaD23)-antibiotic interaction and mechanism of action: insights from experimental and molecular dynamics simulations studies. Front. Pharmacol. 12, https:\/\/doi.org\/10.3389\/fphar.2021.731499 (2021).","DOI":"10.3389\/fphar.2021.731499"},{"key":"1954_CR42","doi-asserted-by":"crossref","unstructured":"Ting, D. S. J., Lakshminarayanan, R., Mohammad, I. & Dua, H. Development of novel human-derived hybrid host defense peptides for infectious keratitis. BMJ Open Ophthalmol. 8, (2023).","DOI":"10.1136\/bmjophth-2023-BCM.4"},{"key":"1954_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-023-00832-0","volume":"23","author":"A Tropsha","year":"2024","unstructured":"Tropsha, A., Isayev, O., Varnek, A., Schneider, G. & Cherkasov, A. Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR. Nat. Rev. Drug Discov. 23, 141\u2013155 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1954_CR44","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s42256-024-00809-7","volume":"6","author":"K Swanson","year":"2024","unstructured":"Swanson, K. et al. Generative AI for designing and validating easily synthesizable and structurally novel antibiotics. Nat. Mach. Intell. 6, 338\u2013353 (2024).","journal-title":"Nat. Mach. Intell."},{"key":"1954_CR45","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41551-021-00689-x","volume":"5","author":"P Das","year":"2021","unstructured":"Das, P. et al. Accelerated antimicrobial discovery via deep generative models and molecular dynamics simulations. Nat. Biomed. Eng. 5, 613\u2013623 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1954_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41512-2","volume":"14","author":"G Turon","year":"2023","unstructured":"Turon, G. et al. First fully-automated AI\/ML virtual screening cascade implemented at a drug discovery centre in Africa. Nat. Commun. 14, 5736 (2023).","journal-title":"Nat. Commun."},{"key":"1954_CR47","doi-asserted-by":"publisher","first-page":"35796","DOI":"10.1109\/ACCESS.2024.3373195","volume":"12","author":"R Alizadehsani","year":"2024","unstructured":"Alizadehsani, R. et al. Explainable artificial intelligence for drug discovery and development: a comprehensive survey. IEEE Access 12, 35796\u201335812 (2024).","journal-title":"IEEE Access"},{"key":"1954_CR48","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s42256-020-00236-4","volume":"2","author":"J Jim\u00e9nez-Luna","year":"2020","unstructured":"Jim\u00e9nez-Luna, J., Grisoni, F. & Schneider, G. Drug discovery with explainable artificial intelligence. Nat. Mach. Intell. 2, 573\u2013584 (2020).","journal-title":"Nat. Mach. Intell."},{"key":"1954_CR49","doi-asserted-by":"publisher","first-page":"6799","DOI":"10.1021\/acs.jcim.4c00720","volume":"64","author":"A Madushanka","year":"2024","unstructured":"Madushanka, A., Laird, E., Clark, C. & Kraka, E. SmartCADD: AI-QM empowered drug discovery platform with explainability. J. Chem. Inf. Model. 64, 6799\u20136813 (2024).","journal-title":"J. Chem. Inf. Model."},{"key":"1954_CR50","unstructured":"OpenAI et al. OpenAI o1 System Card. arXiv https:\/\/ui.adsabs.harvard.edu\/abs\/2024arXiv241216720O (2024)."},{"key":"1954_CR51","unstructured":"Team, G. et al. Gemini: a family of highly capable multimodal models. arXiv https:\/\/ui.adsabs.harvard.edu\/abs\/2023arXiv231211805G (2023)."},{"key":"1954_CR52","unstructured":"DeepSeek-AI et al. DeepSeek-R1: incentivizing reasoning capability in LLMs via reinforcement learning. arXiv https:\/\/ui.adsabs.harvard.edu\/abs\/2025arXiv250112948D (2025)."},{"key":"1954_CR53","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s44222-023-00063-3","volume":"1","author":"A Loewa","year":"2023","unstructured":"Loewa, A., Feng, J. J. & Hedtrich, S. Human disease models in drug development. Nat. Rev. Bioeng. 1, 545\u2013559 (2023).","journal-title":"Nat. Rev. Bioeng."},{"key":"1954_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.medntd.2023.100276","volume":"21","author":"H Shi","year":"2024","unstructured":"Shi, H. et al. Organoid intelligence: integration of organoid technology and artificial intelligence in the new era of in vitro models. Med. Nov. Technol. Devices 21, 100276 (2024).","journal-title":"Med. Nov. Technol. Devices"},{"key":"1954_CR55","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.46188","volume":"8","author":"K Achberger","year":"2019","unstructured":"Achberger, K. et al. Merging organoid and organ-on-a-chip technology to generate complex multi-layer tissue models in a human retina-on-a-chip platform. eLife 8, e46188 (2019).","journal-title":"eLife"},{"key":"1954_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201700028","volume":"7","author":"M Chung","year":"2018","unstructured":"Chung, M. et al. Wet-AMD on a chip: modeling outer blood-retinal barrier in vitro. Adv. Healthc. Mater. 7, 1700028 (2018).","journal-title":"Adv. Healthc. Mater."},{"key":"1954_CR57","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41591-019-0531-2","volume":"25","author":"J Seo","year":"2019","unstructured":"Seo, J. et al. Multiscale reverse engineering of the human ocular surface. Nat. Med. 25, 1310\u20131318 (2019).","journal-title":"Nat. Med."},{"key":"1954_CR58","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1039\/D2LC00983H","volume":"23","author":"D-H Choi","year":"2023","unstructured":"Choi, D.-H. et al. Analyzing angiogenesis on a chip using deep learning-based image processing. Lab Chip 23, 475\u2013484 (2023).","journal-title":"Lab Chip"},{"key":"1954_CR59","doi-asserted-by":"publisher","first-page":"10084","DOI":"10.1021\/acsomega.8b01485","volume":"3","author":"OJ Dressler","year":"2018","unstructured":"Dressler, O. J., Howes, P. D., Choo, J. & deMello, A. J. Reinforcement learning for dynamic microfluidic control. ACS Omega 3, 10084\u201310091 (2018).","journal-title":"ACS Omega"},{"key":"1954_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19058-4","volume":"11","author":"B Schuster","year":"2020","unstructured":"Schuster, B. et al. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat. Commun. 11, 5271 (2020).","journal-title":"Nat. Commun."},{"key":"1954_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38832-8","volume":"14","author":"PJ Tebon","year":"2023","unstructured":"Tebon, P. J. et al. Drug screening at single-organoid resolution via bioprinting and interferometry. Nat. Commun. 14, 3168 (2023).","journal-title":"Nat. Commun."},{"key":"1954_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44162-6","volume":"14","author":"P Mukashyaka","year":"2023","unstructured":"Mukashyaka, P. et al. High-throughput deconvolution of 3D organoid dynamics at cellular resolution for cancer pharmacology with Cellos. Nat. Commun. 14, 8406 (2023).","journal-title":"Nat. Commun."},{"key":"1954_CR63","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer, L. et al. Applied concepts in PBPK modeling: how to build a PBPK\/PD model. CPT Pharmacomet. Syst. Pharm. 5, 516\u2013531 (2016).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"1954_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.41","volume":"2","author":"H Jones","year":"2013","unstructured":"Jones, H. & Rowland-Yeo, K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacomet. Syst. Pharm. 2, e63 (2013).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"1954_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114772","volume":"196","author":"N Wang","year":"2023","unstructured":"Wang, N. et al. How can machine learning and multiscale modeling benefit ocular drug development?. Adv. Drug Deliv. Rev. 196, 114772 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1954_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100901","volume":"82","author":"UB Kompella","year":"2021","unstructured":"Kompella, U. B., Hartman, R. R. & Patil, M. A. Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma. Prog. Retinal Eye Res. 82, 100901 (2021).","journal-title":"Prog. Retinal Eye Res."},{"key":"1954_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97821-3","volume":"11","author":"DSJ Ting","year":"2021","unstructured":"Ting, D. S. J. et al. Hybrid derivative of cathelicidin and human beta defensin-2 against Gram-positive bacteria: a novel approach for the treatment of bacterial keratitis. Sci. Rep. 11, 18304 (2021).","journal-title":"Sci. Rep."},{"key":"1954_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxsci\/kfac101","volume":"191","author":"W-C Chou","year":"2022","unstructured":"Chou, W.-C. & Lin, Z. Machine learning and artificial intelligence in physiologically based pharmacokinetic modeling. Toxicol. Sci. 191, 1\u201314 (2022).","journal-title":"Toxicol. Sci."},{"key":"1954_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102804","volume":"24","author":"J Lu","year":"2021","unstructured":"Lu, J., Deng, K., Zhang, X., Liu, G. & Guan, Y. Neural-ODE for pharmacokinetics modeling and its advantage to alternative machine learning models in predicting new dosing regimens. iScience 24, 102804 (2021).","journal-title":"iScience"},{"key":"1954_CR70","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5414\/CP203800","volume":"59","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Long short-term memory recurrent neural network for pharmacokinetic-pharmacodynamic modeling. Int. J. Clin. Pharm. Ther. 59, 138\u2013146 (2021).","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"1954_CR71","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41588-021-00885-0","volume":"53","author":"JD Szustakowski","year":"2021","unstructured":"Szustakowski, J. D. et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. Nat. Genet. 53, 942\u2013948 (2021).","journal-title":"Nat. Genet."},{"key":"1954_CR72","doi-asserted-by":"crossref","unstructured":"Zhou, W., Li, X., Han, L. & Fan, S. in Network Pharmacology (ed. Li, S.) 35\u201373 (Springer, 2021).","DOI":"10.1007\/978-981-16-0753-0_2"},{"key":"1954_CR73","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41587-022-01520-x","volume":"41","author":"RL Alles\u00f8e","year":"2023","unstructured":"Alles\u00f8e, R. L. et al. Discovery of drug\u2013omics associations in type 2 diabetes with generative deep-learning models. Nat. Biotechnol. 41, 399\u2013408 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1954_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100517","volume":"4","author":"J Wolf","year":"2024","unstructured":"Wolf, J. et al. Using electronic health record data to determine the safety of aqueous humor liquid biopsies for molecular analyses. Ophthalmol. Sci. 4, 100517 (2024).","journal-title":"Ophthalmol. Sci."},{"key":"1954_CR75","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1021\/acs.jproteome.3c00756","volume":"23","author":"J Wolf","year":"2024","unstructured":"Wolf, J. et al. Liquid biopsy proteomics in ophthalmology. J. Proteome Res. 23, 511\u2013522 (2024).","journal-title":"J. Proteome Res."},{"key":"1954_CR76","doi-asserted-by":"publisher","unstructured":"Kato, Y. et al. Age-related maculopathy susceptibility 2 and complement factor H polymorphism and intraocular complement activation in neovascular age-related macular degeneration. Ophthalmol. Sci. 2, https:\/\/doi.org\/10.1016\/j.xops.2022.100167 (2022).","DOI":"10.1016\/j.xops.2022.100167"},{"key":"1954_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2022.110286","volume":"114","author":"J Wolf","year":"2022","unstructured":"Wolf, J. et al. The Human Eye Transcriptome Atlas: a searchable comparative transcriptome database for healthy and diseased human eye tissue. Genomics 114, 110286 (2022).","journal-title":"Genomics"},{"key":"1954_CR78","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.7150\/thno.72947","volume":"12","author":"A Alli-Shaik","year":"2022","unstructured":"Alli-Shaik, A. et al. System-wide vitreous proteome dissection reveals impaired sheddase activity in diabetic retinopathy. Theranostics 12, 6682\u20136704 (2022).","journal-title":"Theranostics"},{"key":"1954_CR79","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1016\/j.cell.2023.09.012","volume":"186","author":"J Wolf","year":"2023","unstructured":"Wolf, J. et al. Liquid-biopsy proteomics combined with AI identifies cellular drivers of eye aging and disease in vivo. Cell 186, 4868\u20134884.e4812 (2023).","journal-title":"Cell"},{"key":"1954_CR80","doi-asserted-by":"publisher","unstructured":"Hallam, T. M. et al. Ocular biomarker profiling after complement factor I gene therapy in geographic atrophy secondary to age-related macular degeneration. medRxiv https:\/\/doi.org\/10.1101\/2024.06.12.24308796 (2024).","DOI":"10.1101\/2024.06.12.24308796"},{"key":"1954_CR81","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/s42256-022-00541-0","volume":"4","author":"D He","year":"2022","unstructured":"He, D., Liu, Q., Wu, Y. & Xie, L. A context-aware deconfounding autoencoder for robust prediction of personalized clinical drug response from cell-line compound screening. Nat. Mach. Intell. 4, 879\u2013892 (2022).","journal-title":"Nat. Mach. Intell."},{"key":"1954_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100875","volume":"80","author":"G Beykin","year":"2021","unstructured":"Beykin, G., Norcia, A. M., Srinivasan, V. J., Dubra, A. & Goldberg, J. L. Discovery and clinical translation of novel glaucoma biomarkers. Prog. Retin. Eye Res. 80, 100875 (2021).","journal-title":"Prog. Retin. Eye Res."},{"key":"1954_CR83","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40135-019-00213-0","volume":"7","author":"G Beykin","year":"2019","unstructured":"Beykin, G. & Goldberg, J. L. Molecular biomarkers for glaucoma. Curr. Ophthalmol. Rep. 7, 171\u2013176 (2019).","journal-title":"Curr. Ophthalmol. Rep."},{"key":"1954_CR84","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1167\/iovs.63.11.16","volume":"63","author":"AM Norcia","year":"2022","unstructured":"Norcia, A. M., Yakovleva, A., Jehangir, N. & Goldberg, J. L. Preferential loss of contrast decrement responses in human glaucoma. Invest. Ophthalmol. Vis. Sci. 63, 16 (2022).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1954_CR85","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1167\/tvst.11.7.12","volume":"11","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. AutoMorph: automated retinal vascular morphology quantification via a deep learning pipeline. Transl. Vis. Sci. Technol. 11, 12\u201312 (2022).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"1954_CR86","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ophtha.2020.09.025","volume":"128","author":"G Moraes","year":"2021","unstructured":"Moraes, G. et al. Quantitative analysis of OCT for neovascular age-related macular degeneration using deep learning. Ophthalmology 128, 693\u2013705 (2021).","journal-title":"Ophthalmology"},{"key":"1954_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100900","volume":"82","author":"JO Li","year":"2021","unstructured":"Li, J. O. et al. Digital technology, tele-medicine and artificial intelligence in ophthalmology: a global perspective. Prog. Retin. Eye Res. 82, 100900 (2021).","journal-title":"Prog. Retin. Eye Res."},{"key":"1954_CR88","doi-asserted-by":"publisher","first-page":"AIoa2300221,","DOI":"10.1056\/AIoa2300221","volume":"1","author":"J Qiu","year":"2024","unstructured":"Qiu, J. et al. Development and Validation of a Multimodal Multitask Vision Foundation Model for Generalist Ophthalmic Artificial Intelligence. NEJM AI 1, AIoa2300221, https:\/\/doi.org\/10.1056\/AIoa2300221 (2024).","journal-title":"NEJM AI"},{"key":"1954_CR89","doi-asserted-by":"publisher","unstructured":"Xiong, F. et al. Ocular signs and testing most compatible with sarcoidosis-associated uveitis: a latent class analysis. Ophthalmol. Sci. 4, https:\/\/doi.org\/10.1016\/j.xops.2024.100503 (2024).","DOI":"10.1016\/j.xops.2024.100503"},{"key":"1954_CR90","doi-asserted-by":"publisher","unstructured":"Holland, R. et al. Deep-learning-based clustering of OCT images for biomarker discovery in age-related macular degeneration (PINNACLE study report 4). Ophthalmol. Sci. https:\/\/doi.org\/10.1016\/j.xops.2024.100543 (2024).","DOI":"10.1016\/j.xops.2024.100543"},{"key":"1954_CR91","doi-asserted-by":"publisher","unstructured":"Moraes, G. et al. Quantifying changes on OCT in eyes receiving treatment for neovascular age-related macular degeneration. Ophthalmol. Sci. 4, https:\/\/doi.org\/10.1016\/j.xops.2024.100570 (2024).","DOI":"10.1016\/j.xops.2024.100570"},{"key":"1954_CR92","doi-asserted-by":"publisher","unstructured":"Massengill, M. T., Cubillos, S., Sheth, N., Sethi, A. & Lim, J. I. Response of diabetic macular edema to anti-VEGF medications correlates with improvement in macular vessel architecture measured with OCT angiography. Ophthalmol. Sci. 4, https:\/\/doi.org\/10.1016\/j.xops.2024.100478 (2024).","DOI":"10.1016\/j.xops.2024.100478"},{"key":"1954_CR93","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.oret.2021.05.002","volume":"5","author":"M Gallardo","year":"2021","unstructured":"Gallardo, M. et al. Machine learning can predict anti\u2013VEGF treatment demand in a treat-and-extend regimen for patients with neovascular AMD, DME, and RVO associated macular edema. Ophthalmol. Retin. 5, 604\u2013624 (2021).","journal-title":"Ophthalmol. Retin."},{"key":"1954_CR94","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s00417-021-05247-4","volume":"259","author":"X Zhao","year":"2021","unstructured":"Zhao, X. et al. Optical coherence tomography-based short-term effect prediction of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration using sensitive structure guided network. Graefes Arch. Clin. Exp. Ophthalmol. 259, 3261\u20133269 (2021).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"1954_CR95","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/IAE.0000000000002898","volume":"41","author":"H Lee","year":"2021","unstructured":"Lee, H., Kim, S., Kim, M. A., Chung, H. & Kim, H. C. Post-treatment prediction of optical coherence tomography using a conditional generative adversarial network in age-related macular degeneration. Retina 41, 572\u2013580 (2021).","journal-title":"Retina"},{"key":"1954_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2022.101160","volume":"97","author":"L Schmetterer","year":"2023","unstructured":"Schmetterer, L. et al. Endpoints for clinical trials in ophthalmology. Prog. Retin. Eye Res. 97, 101160 (2023).","journal-title":"Prog. Retin. Eye Res."},{"key":"1954_CR97","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/IJG.0000000000002066","volume":"31","author":"MT Sun","year":"2022","unstructured":"Sun, M. T. et al. Structural and metabolic imaging after short-term use of the balance goggles system in glaucoma patients: a pilot study. J. Glaucoma 31, 634\u2013638 (2022).","journal-title":"J. Glaucoma"},{"key":"1954_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.964197","volume":"13","author":"LA Levin","year":"2022","unstructured":"Levin, L. A., Patrick, C., Choudry, N. B., Sharif, N. A. & Goldberg, J. L. Neuroprotection in neurodegenerations of the brain and eye: lessons from the past and directions for the future. Front. Neurol. 13, 964197 (2022).","journal-title":"Front. Neurol."},{"key":"1954_CR99","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13024-022-00524-0","volume":"17","author":"LK Wareham","year":"2022","unstructured":"Wareham, L. K. et al. Solving neurodegeneration: common mechanisms and strategies for new treatments. Mol. Neurodegener. 17, 23 (2022).","journal-title":"Mol. Neurodegener."},{"key":"1954_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100566","volume":"4","author":"DJ Williamson","year":"2024","unstructured":"Williamson, D. J. et al. Artificial intelligence to facilitate clinical trial recruitment in age-related macular degeneration. Ophthalmol. Sci. 4, 100566 (2024).","journal-title":"Ophthalmol. Sci."},{"key":"1954_CR101","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1016\/S2589-7500(23)00052-3","volume":"5","author":"E Vayena","year":"2023","unstructured":"Vayena, E., Blasimme, A. & Sugarman, J. Decentralised clinical trials: ethical opportunities and challenges. Lancet Digital Health 5, e390\u2013e394 (2023).","journal-title":"Lancet Digital Health"},{"key":"1954_CR102","doi-asserted-by":"publisher","unstructured":"Teo, Z. L. et al. Federated machine learning in healthcare: a systematic review on clinical applications and technical architecture. Cell Rep. Med. 5, https:\/\/doi.org\/10.1016\/j.xcrm.2024.101419 (2024).","DOI":"10.1016\/j.xcrm.2024.101419"},{"key":"1954_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1017-7","volume":"16","author":"P Pallmann","year":"2018","unstructured":"Pallmann, P. et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 16, 29 (2018).","journal-title":"BMC Med."},{"key":"1954_CR104","doi-asserted-by":"publisher","first-page":"e066249","DOI":"10.1136\/bmjopen-2022-066249","volume":"13","author":"K Huckvale","year":"2023","unstructured":"Huckvale, K. et al. Protocol for a bandit-based response adaptive trial to evaluate the effectiveness of brief self-guided digital interventions for reducing psychological distress in university students: the Vibe Up study. BMJ Open 13, e066249 (2023).","journal-title":"BMJ Open"},{"key":"1954_CR105","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13897","volume":"17","author":"AA Vidovszky","year":"2024","unstructured":"Vidovszky, A. A. et al. Increasing acceptance of AI-generated digital twins through clinical trial applications. Clin. Transl. Sci. 17, e13897 (2024).","journal-title":"Clin. Transl. Sci."},{"key":"1954_CR106","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/17460441.2023.2273839","volume":"19","author":"M Bordukova","year":"2024","unstructured":"Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F. & Menden, M. P. Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. Expert Opin. Drug Discov. 19, 33\u201342 (2024).","journal-title":"Expert Opin. Drug Discov."},{"key":"1954_CR107","doi-asserted-by":"publisher","first-page":"11074","DOI":"10.3390\/ijms252011074","volume":"25","author":"G Visioli","year":"2024","unstructured":"Visioli, G. et al. Proliferative vitreoretinopathy in retinal detachment: perspectives on building a digital twin model using nintedanib. Int. J. Mol. Sci. 25, 11074 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1954_CR108","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/technologies12040055","volume":"12","author":"M-E Iliu\u0163\u0103","year":"2024","unstructured":"Iliu\u0163\u0103, M.-E. et al. Digital twin models for personalised and predictive medicine in ophthalmology. Technologies 12, 55 (2024).","journal-title":"Technologies"},{"key":"1954_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-00329-9","volume":"3","author":"F Li","year":"2020","unstructured":"Li, F. et al. Development and clinical deployment of a smartphone-based visual field deep learning system for glaucoma detection. npj Digital Med. 3, 123 (2020).","journal-title":"npj Digital Med."},{"key":"1954_CR110","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41591-022-02180-9","volume":"29","author":"W Chen","year":"2023","unstructured":"Chen, W. et al. Early detection of visual impairment in young children using a smartphone-based deep learning system. Nat. Med. 29, 493\u2013503 (2023).","journal-title":"Nat. Med."},{"key":"1954_CR111","doi-asserted-by":"publisher","unstructured":"Li, J. et al. Integrated image-based deep learning and language models for primary diabetes care. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03139-8 (2024).","DOI":"10.1038\/s41591-024-03139-8"},{"key":"1954_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-022-00617-6","volume":"5","author":"N Zong","year":"2022","unstructured":"Zong, N. et al. Computational drug repurposing based on electronic health records: a scoping review. npj Digital Med. 5, 77 (2022).","journal-title":"npj Digital Med."},{"key":"1954_CR113","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s42256-020-00276-w","volume":"3","author":"R Liu","year":"2021","unstructured":"Liu, R., Wei, L. & Zhang, P. A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data. Nat. Mach. Intell. 3, 68\u201375 (2021).","journal-title":"Nat. Mach. Intell."},{"key":"1954_CR114","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","volume":"18","author":"BR Beck","year":"2020","unstructured":"Beck, B. R., Shin, B., Choi, Y., Park, S. & Kang, K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput. Struct. Biotechnol. J. 18, 784\u2013790 (2020).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"1954_CR115","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.1016\/S2589-7500(20)30192-8","volume":"2","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y., Wang, F., Tang, J., Nussinov, R. & Cheng, F. Artificial intelligence in COVID-19 drug repurposing. Lancet Digital Health 2, e667\u2013e676 (2020).","journal-title":"Lancet Digital Health"},{"key":"1954_CR116","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41433-023-02619-4","volume":"38","author":"DSJ Ting","year":"2024","unstructured":"Ting, D. S. J., Tan, T. F. & Ting, D. S. W. ChatGPT in ophthalmology: the dawn of a new era?. Eye38, 4\u20137 (2024).","journal-title":"Eye"},{"key":"1954_CR117","doi-asserted-by":"publisher","first-page":"e0000341","DOI":"10.1371\/journal.pdig.0000341","volume":"3","author":"AJ Thirunavukarasu","year":"2024","unstructured":"Thirunavukarasu, A. J. et al. Large language models approach expert-level clinical knowledge and reasoning in ophthalmology: a head-to-head cross-sectional study. PLoS Digit. Health 3, e0000341 (2024).","journal-title":"PLoS Digit. Health"},{"key":"1954_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01038-3","volume":"7","author":"C Yan","year":"2024","unstructured":"Yan, C. et al. Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer\u2019s disease with real-world clinical validation. npj Digital Med. 7, 46 (2024).","journal-title":"npj Digital Med."},{"key":"1954_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51980-9","volume":"15","author":"B Ouyang","year":"2024","unstructured":"Ouyang, B. et al. AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer. Nat. Commun. 15, 7560 (2024).","journal-title":"Nat. Commun."},{"key":"1954_CR120","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/postmj\/qgad135","volume":"100","author":"AR Katwaroo","year":"2023","unstructured":"Katwaroo, A. R., Adesh, V. S., Lowtan, A. & Umakanthan, S. The diagnostic, therapeutic, and ethical impact of artificial intelligence in modern medicine. Postgrad. Med. J. 100, 289\u2013296 (2023).","journal-title":"Postgrad. Med. J."},{"key":"1954_CR121","first-page":"194","volume":"294","author":"K Narmadha","year":"2022","unstructured":"Narmadha, K. & Varalakshmi, P. Federated Learning in Healthcare: a privacy preserving approach. Stud. Health Technol. Inf. 294, 194\u2013198 (2022).","journal-title":"Stud. Health Technol. Inf."},{"key":"1954_CR122","unstructured":"U.S. Food & Drug Administration. Artificial Intelligence in Software as a Medical Device (SaMD). FDA (published 25 March 2025; accessed 20 August 2025)."},{"key":"1954_CR123","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jama.2024.21451","volume":"333","author":"HJ Warraich","year":"2025","unstructured":"Warraich, H. J., Tazbaz, T. & Califf, R. M. FDA perspective on the regulation of artificial intelligence in health care and biomedicine. JAMA 333, 241\u2013247 (2025).","journal-title":"JAMA"},{"key":"1954_CR124","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/ph18010047","volume":"18","author":"F Mirakhori","year":"2025","unstructured":"Mirakhori, F. & Niazi, S. K. Harnessing the AI\/ML in drug and biological products discovery and development: the regulatory perspective. Pharmaceuticals 18, 47 (2025).","journal-title":"Pharmaceuticals"},{"key":"1954_CR125","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41587-023-02029-7","volume":"41","author":"M Hutson","year":"2023","unstructured":"Hutson, M. AI for drug discovery is booming, but who owns the patents?. Nat. Biotechnol. 41, 1494\u20131496 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1954_CR126","unstructured":"Krumplitsch, S. Generative AI, drug discovery, and US patent law. https:\/\/www.dlapiper.com\/en-cl\/insights\/publications\/synthesis\/2024\/generative-ai-drug-discovery-and-us-patent-law (2024)."},{"key":"1954_CR127","unstructured":"School, C. L. 35 U.S. Code \u00a7 112\u2014Specification. https:\/\/www.law.cornell.edu\/uscode\/text\/35\/112 (2024)."},{"key":"1954_CR128","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jocn.2019.03.001","volume":"64","author":"KH Keskinbora","year":"2019","unstructured":"Keskinbora, K. H. Medical ethics considerations on artificial intelligence. J. Clin. Neurosci. 64, 277\u2013282 (2019).","journal-title":"J. Clin. Neurosci."},{"key":"1954_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102887","volume":"77","author":"ZZ Ong","year":"2024","unstructured":"Ong, Z. Z. et al. Diagnostic performance of deep learning for infectious keratitis: a systematic review and meta-analysis. EClinicalMedicine 77, 102887 (2024).","journal-title":"EClinicalMedicine"},{"key":"1954_CR130","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.rce.2024.01.007","volume":"224","author":"L Inglada Galiana","year":"2024","unstructured":"Inglada Galiana, L., Corral Gudino, L. & Miramontes Gonz\u00e1lez, P. Ethics and artificial intelligence. Rev. Cl\u00edn. Esp.224, 178\u2013186 (2024).","journal-title":"Rev. Cl\u00edn. Esp."},{"key":"1954_CR131","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41591-022-01772-9","volume":"28","author":"B Vasey","year":"2022","unstructured":"Vasey, B. et al. Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI. Nat. Med. 28, 924\u2013933 (2022).","journal-title":"Nat. Med."},{"key":"1954_CR132","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41591-020-1034-x","volume":"26","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Nat. Med. 26, 1364\u20131374 (2020).","journal-title":"Nat. Med."},{"key":"1954_CR133","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41591-020-1037-7","volume":"26","author":"S Cruz Rivera","year":"2020","unstructured":"Cruz Rivera, S. et al. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. Nat. Med. 26, 1351\u20131363 (2020).","journal-title":"Nat. Med."},{"key":"1954_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.108734","volume":"179","author":"A Gangwal","year":"2024","unstructured":"Gangwal, A., Ansari, A., Ahmad, I., Azad, A. K. & Wan Sulaiman, W. M. A. Current strategies to address data scarcity in artificial intelligence-based drug discovery: a comprehensive review. Comput. Biol. Med. 179, 108734 (2024).","journal-title":"Comput. Biol. Med."},{"key":"1954_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50834-6","volume":"14","author":"B Macedo","year":"2024","unstructured":"Macedo, B., Ribeiro Vaz, I. & Taveira Gomes, T. MedGAN: optimized generative adversarial network with graph convolutional networks for novel molecule design. Sci. Rep. 14, 1212 (2024).","journal-title":"Sci. Rep."},{"key":"1954_CR136","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/ddr.22115","volume":"84","author":"PC Tiwari","year":"2023","unstructured":"Tiwari, P. C., Pal, R., Chaudhary, M. J. & Nath, R. Artificial intelligence revolutionizing drug development: exploring opportunities and challenges. Drug Dev. Res. 84, 1652\u20131663 (2023).","journal-title":"Drug Dev. Res."},{"key":"1954_CR137","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3390\/ph16060891","volume":"16","author":"A Blanco-Gonz\u00e1lez","year":"2023","unstructured":"Blanco-Gonz\u00e1lez, A. et al. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals 16, 891 (2023).","journal-title":"Pharmaceuticals"},{"key":"1954_CR138","doi-asserted-by":"crossref","unstructured":"Jalali, R., Nogueira-Rodrigues, A., Das, A., Sirohi, B. & Panda, P. K. Drug development in low- and middle-income countries: opportunity or exploitation? Am. Soc. Clin. Oncol. Educ. Book 3\u201310 (2022).","DOI":"10.1200\/EDBK_10033"},{"key":"1954_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04951-6","volume":"22","author":"H Ibrahim","year":"2021","unstructured":"Ibrahim, H. et al. Reporting guidelines for clinical trials of artificial intelligence interventions: the SPIRIT-AI and CONSORT-AI guidelines. Trials 22, 11 (2021).","journal-title":"Trials"},{"key":"1954_CR140","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","volume":"391","author":"BE Sands","year":"2024","unstructured":"Sands, B. E. et al. Phase 2 trial of anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis. N. Engl. J. Med. 391, 1119\u20131129 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1954_CR141","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1158\/1538-7445.AM2023-502","volume":"83","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Abstract 502: ISM3091, a novel selective USP1 inhibitor as a targeted anticancer therapy. Cancer Res. 83, 502\u2013502 (2023).","journal-title":"Cancer Res."},{"key":"1954_CR142","unstructured":"Insilico. A Small Molecule KAT6 Inhibitor as a Potential Treatment of ER+ HER2- Breast Cancer (Entering IND). https:\/\/insilico.com\/pipeline_target_kat6 (2024)."},{"key":"1954_CR143","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41587-024-02143-0","volume":"43","author":"F Ren","year":"2025","unstructured":"Ren, F. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat. Biotechnol. 43, 63\u201375 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1954_CR144","doi-asserted-by":"publisher","unstructured":"Booq, R. Y., Tawfik, E. A., Alfassam, H. A., Alfahad, A. J. & Alyamani, E. J. Assessment of the antibacterial efficacy of halicin against pathogenic bacteria. Antibiotics 10, https:\/\/doi.org\/10.3390\/antibiotics10121480 (2021).","DOI":"10.3390\/antibiotics10121480"},{"key":"1954_CR145","doi-asserted-by":"publisher","first-page":"S365","DOI":"10.1016\/j.jtho.2023.09.642","volume":"18","author":"J Treat","year":"2023","unstructured":"Treat, J. et al. P2.12-07 phase II trial of LP-300 + pemetrexed\/carboplatin in patients who never smoked with lung adenocarcinoma after TKI progression. J. Thorac. Oncol. 18, S365 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1954_CR146","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/2767-9764.CRC-23-0554","volume":"4","author":"A Kulkarni","year":"2024","unstructured":"Kulkarni, A. et al. LP-184, a novel acylfulvene molecule, exhibits anticancer activity against diverse solid tumors with homologous recombination deficiency. Cancer Res. Commun. 4, 1199\u20131210 (2024).","journal-title":"Cancer Res. Commun."},{"key":"1954_CR147","doi-asserted-by":"publisher","first-page":"597","DOI":"10.18632\/oncotarget.28454","volume":"14","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin\u2019s lymphoma models and in cells deficient in DNA damage repair. Oncotarget 14, 597\u2013611 (2023).","journal-title":"Oncotarget"},{"key":"1954_CR148","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/s41433-022-02077-4","volume":"37","author":"U Schmidt-Erfurth","year":"2023","unstructured":"Schmidt-Erfurth, U. et al. Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis. Eye 37, 1160\u20131169 (2023).","journal-title":"Eye"},{"key":"1954_CR149","first-page":"536","volume":"108","author":"DJ Fu","year":"2024","unstructured":"Fu, D. J. et al. Deep-learning automated quantification of longitudinal OCT scans demonstrates reduced RPE loss rate, preservation of intact macular area and predictive value of isolated photoreceptor degeneration in geographic atrophy patients receiving C3 inhibition treatment. Br. J. Ophthalmol. 108, 536\u2013545 (2024).","journal-title":"Br. J. Ophthalmol."},{"key":"1954_CR150","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.oret.2022.08.003","volume":"7","author":"W-D Vogl","year":"2023","unstructured":"Vogl, W.-D. et al. Predicting topographic disease progression and treatment response of pegcetacoplan in geographic atrophy quantified by deep learning. Ophthalmol. Retin. 7, 4\u201313 (2023).","journal-title":"Ophthalmol. Retin."},{"key":"1954_CR151","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1001\/jamaophthalmol.2020.2457","volume":"138","author":"PK Roberts","year":"2020","unstructured":"Roberts, P. K. et al. Quantification of fluid resolution and visual acuity gain in patients with diabetic macular edema using deep learning: a post hoc analysis of a randomized clinical trial. JAMA Ophthalmol. 138, 945\u2013953 (2020).","journal-title":"JAMA Ophthalmol."},{"key":"1954_CR152","doi-asserted-by":"publisher","unstructured":"Schmidt-Erfurth, U. et al. Disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT. Ophthalmology https:\/\/doi.org\/10.1016\/j.ophtha.2024.08.017 (2024).","DOI":"10.1016\/j.ophtha.2024.08.017"},{"key":"1954_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100565","volume":"4","author":"Z Mulyukov","year":"2024","unstructured":"Mulyukov, Z. et al. Artificial intelligence-based disease activity monitoring to personalized neovascular age-related macular degeneration treatment: a feasibility study. Ophthalmol. Sci. 4, 100565 (2024).","journal-title":"Ophthalmol. Sci."},{"key":"1954_CR154","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.oret.2023.11.010","volume":"8","author":"RS Chandra","year":"2024","unstructured":"Chandra, R. S. & Ying, G. S. Predicting visual acuity responses to anti-VEGF treatment in the comparison of age-related macular degeneration treatments trials using machine learning. Ophthalmol. Retin. 8, 419\u2013430 (2024).","journal-title":"Ophthalmol. Retin."},{"key":"1954_CR155","doi-asserted-by":"publisher","unstructured":"Kikuchi, Y. et al. Machine learning to predict faricimab treatment outcome in neovascular age-related macular degeneration. Ophthalmol. Sci. 4, https:\/\/doi.org\/10.1016\/j.xops.2023.100385 (2024).","DOI":"10.1016\/j.xops.2023.100385"},{"key":"1954_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100319","volume":"3","author":"A Maunz","year":"2023","unstructured":"Maunz, A. et al. Machine learning to predict response to ranibizumab in neovascular age-related macular degeneration. Ophthalmol. Sci. 3, 100319 (2023).","journal-title":"Ophthalmol. Sci."},{"key":"1954_CR157","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1167\/iovs.16-21053","volume":"58","author":"H Bogunovi\u0107","year":"2017","unstructured":"Bogunovi\u0107, H. et al. Prediction of anti-VEGF treatment requirements in neovascular AMD using a machine learning approach. Invest. Ophthalmol. Vis. Sci. 58, 3240\u20133248 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1954_CR158","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1167\/tvst.12.1.18","volume":"12","author":"RS Chandra","year":"2023","unstructured":"Chandra, R. S. & Ying, G. S. Evaluation of multiple machine learning models for predicting number of anti-VEGF injections in the comparison of AMD treatment trials (CATT). Transl. Vis. Sci. Technol. 12, 18 (2023).","journal-title":"Transl. Vis. Sci. Technol."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01954-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01954-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01954-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:04:11Z","timestamp":1758798251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01954-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":158,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1954"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-01954-y","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.S.W.T. holds a patent on a deep learning system for the detection of retinal diseases (10201706186V) and a computer-implemented method for training an image classifier using weakly annotated training data (10201901083Y) and stocks at EyRIS, Singapore and aISIGHT. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"573"}}